(Q37814208)

23 August 2017

1 reference

title

Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model (English)

1 reference

23 August 2017

1 reference

Wim Maes

1

1 reference

23 August 2017

Stefaan W Van Gool

series ordinal

2

1 reference

23 August 2017

publication date

1 December 2010

1 reference

Cancer Immunology, Immunotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

60

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

153-160

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-010-0946-6

23 August 2017

exact match

0 references

cites work

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

A comparison of treatment results for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Stem and progenitor cell-mediated tumor selective gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Recent advances in the treatment of malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Mouse models of brain tumors and their applications in preclinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Development of a novel mouse glioma model using lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Antitumor cytotoxic T-cell response induced by a survivin peptide mimic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

TLR ligands in the local treatment of established intracerebral murine gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Adoptive T cell therapy for cancer in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Monoclonal antibodies for brain tumour treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Dendritic cell-based immunotherapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Gene therapy for human malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Cancer treatment: the combination of vaccination with other therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Tumor vaccination for high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0946-6

10.1007/S00262-010-0946-6

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference